Literature DB >> 22553543

Macular atrophy after combined intravitreal triamcinolone and photodynamic therapy to treat choroidal neovascularization.

José M Ruiz-Moreno1, Javier A Montero, Pedro Amat, Francisco Lugo.   

Abstract

AIM: To report the appearance of choriocapillaris atrophy after combined high dose intravitreal triamcinolone acetonide (TA) and photodynamic therapy (PDT) to treat choroidal neovascularization (CNV) associated with age related macular degeneration (AMD).
METHODS: The present study was retrospective about non-randomized interventional case series. Fifty-one consecutive eyes with subfoveal (all types) CNV associated with AMD were treated by PDT and intravitreal (19.4±2.1)mg per 0.1mL TA at the Alicante Institute of Ophthalmology. The appearance of macular choriocapillaris and retinal pigment epithelium (RPE) atrophy was considered at two years follow-up. Thirty consecutive eyes treated by PDT alone, matched for age, sex, and type and size of CNV were considered as control group.
RESULTS: Twenty-one of 47 eyes in the study group (45%) and 7 of 30 eyes in the control group (23%) developed macular RPE and choriocapillaris atrophy in the treated area at month 24 (P=0.04, Chi-square test). The greatest diameter of the atrophic areas averaged (5044±1666)µm in the study group vs (4345±1550)µm in the control group. Mean final best corrected visual acuity (logarithm of minimal angle of resolution) was (0.87±0.33) in the cases with RPE atrophy vs (0.66±0.26) in the cases with no RPE atrophy in the study group (P=0.11, Mann-Whitney U test).
CONCLUSION: The association of high doses of intravitreal TA and PDT may increase the risk for RPE and choriocapillaris atrophy.

Entities:  

Keywords:  age related macular degeneration; choriocapillaris atrophy; intravitreous triamcinolone; photodynamic therapy; retinal pigment epithelium atrophy

Year:  2010        PMID: 22553543      PMCID: PMC3340762          DOI: 10.3980/j.issn.2222-3959.2010.02.16

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  18 in total

1.  Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration.

Authors:  N T Ranson; R P Danis; T A Ciulla; L Pratt
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

2.  Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.

Authors:  Albert J Augustin; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2005-12-19       Impact factor: 12.079

Review 3.  Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases.

Authors:  Jost B Jonas; Ingrid Kreissig; Robert Degenring
Journal:  Prog Retin Eye Res       Date:  2005-03-29       Impact factor: 21.198

4.  Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema.

Authors:  J B Jonas; A Söfker
Journal:  Am J Ophthalmol       Date:  2001-09       Impact factor: 5.258

5.  Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.

Authors:  Jeffrey S Heier; David S Boyer; Thomas A Ciulla; Philip J Ferrone; J Michael Jumper; Ronald C Gentile; Debbi Kotlovker; Carol Y Chung; Robert Y Kim
Journal:  Arch Ophthalmol       Date:  2006-11

6.  Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females.

Authors:  Laurence Postelmans; Brigitte Pasteels; Pascale Coquelet; Hind El Ouardighi; Claire Verougstraete; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2004-11       Impact factor: 5.258

7.  Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid.

Authors:  Ivana K Kim; Deeba Husain; Norman Michaud; Edward Connolly; Anne Marie Lane; Khayyam Durrani; Ali Hafezi-Moghadam; Evangelos S Gragoudas; Charles A O'Neill; Joseph C Beyer; Joan W Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-01       Impact factor: 4.799

8.  Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization.

Authors:  Richard F Spaide; John Sorenson; Leandro Maranan
Journal:  Ophthalmology       Date:  2005-02       Impact factor: 12.079

9.  Concentric retinal pigment epithelium atrophy after a single photodynamic therapy.

Authors:  Joachim Wachtlin; Tim Behme; Heinrich Heimann; Ulrich Kellner; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-05-07       Impact factor: 3.117

10.  Prolongation of choroidal hypofluorescence following combined verteporfin photodynamic therapy and intravitreal triamcinolone acetonide injection.

Authors:  Jeffrey K Luttrull; Charles J Spink
Journal:  Retina       Date:  2007 Jul-Aug       Impact factor: 4.256

View more
  2 in total

1.  Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD).

Authors:  Tsuyoshi Otsuji; Yoshimi Nagai; Kenichiro Sho; Akiko Tsumura; Naoko Koike; Mei Tsuda; Tetsuya Nishimura; Kanji Takahashi
Journal:  Clin Ophthalmol       Date:  2013-07-22

2.  Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits.

Authors:  You-Fan Ye; Yong-Feng Gao; Hua-Tao Xie; Hai-Jun Wang
Journal:  Mol Vis       Date:  2014-05-13       Impact factor: 2.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.